TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) Director Stephanie Lovell sold 4,900 shares of the stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $57.99, for a total value of $284,151.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
TransMedics Group Price Performance
Shares of TMDX opened at $59.84 on Friday. The company has a quick ratio of 11.21, a current ratio of 12.11 and a debt-to-equity ratio of 0.31. TransMedics Group, Inc. has a 1 year low of $10.00 and a 1 year high of $60.91. The company has a 50 day simple moving average of $47.92 and a two-hundred day simple moving average of $40.82.
TransMedics Group (NASDAQ:TMDX – Get Rating) last posted its earnings results on Thursday, November 3rd. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.15. TransMedics Group had a negative net margin of 58.78% and a negative return on equity of 46.03%. The firm had revenue of $25.68 million during the quarter, compared to analyst estimates of $18.96 million. Sell-side analysts anticipate that TransMedics Group, Inc. will post -1.3 earnings per share for the current year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Several research firms have weighed in on TMDX. JPMorgan Chase & Co. upgraded shares of TransMedics Group from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $26.00 to $48.00 in a research report on Tuesday, August 2nd. Canaccord Genuity Group boosted their price target on shares of TransMedics Group from $58.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, November 4th. Morgan Stanley upped their price target on shares of TransMedics Group from $45.00 to $54.00 and gave the stock an “equal weight” rating in a report on Friday, November 4th. Cowen raised their price target on shares of TransMedics Group from $45.00 to $50.00 in a report on Tuesday, August 2nd. Finally, Oppenheimer raised their price target on shares of TransMedics Group from $40.00 to $45.00 and gave the company an “outperform” rating in a research report on Tuesday, August 2nd. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $49.14.
About TransMedics Group
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
- Get a free copy of the StockNews.com research report on TransMedics Group (TMDX)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.